LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 2004-2013

  King, Constance ^a   Diaz, H B ^a   McNeely, Samuel ^a   Barnard, Darlene ^a   Dempsey, Jack ^a   Blosser, Wayne ^a   Beckmann, Richard ^a   Barda, David ^a   Marshall, Mark S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CDC25A PROTEIN; CHECKPOINT KINASE 1; DNA; DOUBLE STRANDED DNA; DOXORUBICIN; FIRTECAN; GEMCITABINE; LY 2606368; NITRILE; PHOSPHOPROTEIN; PHOSPHORYLATED H2AX; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; RPA2 PROTEIN; STAUROSPORINE; TUMOR PROTEIN; UNCLASSIFIED DRUG; CDC25A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; PREXASERTIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHROMOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; DNA REPLICATION; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MITOSIS RATE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; S PHASE CELL CYCLE CHECKPOINT; TREATMENT RESPONSE; TUNEL ASSAY; ANIMAL; CELL CYCLE S PHASE; CHEMISTRY; DISEASE MODEL; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPLICATION; FEMALE; HUMANS; MICE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZINES; PYRAZOLES; S PHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942154757     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1037     Document Type: Article

References (36)

1. Hartley JA, Hochhauser D. Small molecule drugs - optimizing DNA damaging agent-based therapeutics. Curr Opin Pharmacol 2012;12: 398-402.
2. Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J 2013;19:200-7.
3. Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 2013;20: 648-59.
4. Medema RH, Macurek L. Checkpoint control and cancer. Oncogene 2012; 31:2601-13.
5. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006;209:13-20.
6. Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer 2014;134:1013-23.
7. McNeely S, Beckmann R, Bence Lin AK. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014;142: 1-10.
8. Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol 2013;76:358-69.
9. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005;25:3553-62.
10. Jones RM, Petermann E. Replication fork dynamics and the DNA damage response. Biochem J 2012;443:13-26.
11. Scorah J, McGowan CH. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009;8:1036-43.
12. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006;26: 3319-26.
13. Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013;155:1088-103.
14. Allen C, Ashley AK, Hromas R, Nickoloff JA. More forks on the road to replication stress recovery. J Mol Cell Biol 2011;3:4-12.
15. Budzowska M, Kanaar R. Mechanisms of dealing with DNA damage-induced replication problems. Cell Biochem Biophys 2009;53:17-31.
16. Jia Y, Song W, Zhang F, Yan J, Yang Q. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene 2013;32:1943-9.
17. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 2014;32:213-26.
18. Low J, Shuguang H, Dowless M, Blosser W, Vincent T, Davis S, et al. High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides. J Biomol Screen 2007;12:775-88.
19. Bayani J, Squire JA. Preparation of cytogenetic specimens from tissue samples. In:Bonifacino JS, editor. Current protocols in cell biology. New Jersey: Wiley; 2004; p. 22.2.1-22.2.15.
20. Deng W, Tsao SW, Lucas JN, Leung CS, Cheung AL. A new method for improving metaphase chromosome spreading. Cytometry A 2003;51: 46-51.
21. Gallagher SR. One-dimensional SDS gel electrophoresis of proteins. Current Protoc Protein Sci 2012;Chapter 10:Unit 10 1 1-44.
22. Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs 2014;32:955-68.
23. Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther 2014;13:1442-56.
24. Kitazumi I, Tsukahara M. Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J 2011;278:427-41.
25. Merrick CJ, Jackson D, Diffley JF. Visualization of altered replication dynamics after DNA damage in human cells. J Biol Chem 2004;279: 20067-75.
26. Unno J, Takagi M, Piao J, Sugimoto M, Honda F, Maeda D, et al. Artemis-dependent DNA double-strand break formation at stalled replication forks. Cancer Sci 2013;104:703-10.
27. Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res 2012;18:5650-61.
28. Bryant C, Scriven K, Massey AJ. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells. Mol Cancer 2014;13:147.
29. Guo C, Kumagai A, Schlacher K, Shevchenko A, Dunphy WG. Interaction of Chk1 with Treslin negatively regulates the initiation of chromosomal DNA replication. Mol Cell 2015;57:492-505.
30. Thompson R, Montano R, Eastman A. The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition. PLoS ONE 2012;7:e44021.
31. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
32. Guillotin D, Martin SA. Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp Cell Res 2014;329:110-5.
33. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010;31:955-60.
34. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011;102:663-9.
35. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 2011;17:401-5.
36. Bolcun-Filas E, Rinaldi VD, White ME, Schimenti JC. Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science 2014;343:533-6.